Evaluation and follow-up of antibody formation after CoronaVac vaccine.
Journal
Revista da Associacao Medica Brasileira (1992)
ISSN: 1806-9282
Titre abrégé: Rev Assoc Med Bras (1992)
Pays: Brazil
ID NLM: 9308586
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
08
2022
accepted:
28
08
2022
pubmed:
9
12
2022
medline:
24
12
2022
entrez:
8
12
2022
Statut:
epublish
Résumé
The aim of this study was to monitor the time-dependent change by evaluating the antibody levels at the 4th, 7th, 10th, 13th, and 16th weeks after the second dose of the CoronaVac vaccine. The study group (n=65) were between 21 and 60 years old and received two doses of the CoronaVac vaccine. Blood samples were collected after 4th, 7th, 10th, 13th, and 16th weeks of the second dose of the vaccine administration. There was a coronavirus disease 2019 recovered group (n=29) who were SARS-CoV-2 real-time PCR test result positive before the vaccination period, and no coronavirus disease 2019 history group (n=36). Age, BMI, gender, smoking, comorbidity, coronavirus disease 2019 contact history, and working in the coronavirus disease 2019 service history of the individuals were recorded. No statistically significant difference was found in the descriptive findings of the individuals according to coronavirus disease 2019 recovered group and no coronavirus disease 2019 history group. It was observed that antibody levels in the coronavirus disease 2019 recovered group were found to be higher for each period of serum collection compared to the no coronavirus disease 2019 history group, which were statistically significant. The distribution curves of the antibody levels according to the timing of blood collection in coronavirus disease 2019 recovered group, no coronavirus disease 2019 history group, and total subjects were extrapolated, and it was observed that the estimated time for the antibodies to reach the threshold value of the test was 214, 145, and 166 days after vaccination. It is important to make booster doses, as the CoronaVac vaccine will lose its effect after the fifth month due to the decrease in Ab levels. In addition, since the antibody levels decrease later in those who have a history of coronavirus disease 2019 infection and are vaccinated, individuals who have no previous history of coronavirus disease 2019 should be given priority for vaccination.
Identifiants
pubmed: 36477105
pii: S0104-42302022005015205
doi: 10.1590/1806-9282.20221074
pmc: PMC9779953
pii:
doi:
Substances chimiques
sinovac COVID-19 vaccine
0
Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1769-1773Références
Emerg Infect Dis. 2020 Jul;26(7):1470-1477
pubmed: 32255761
Mikrobiyol Bul. 2022 Jul;56(3):566-573
pubmed: 35960246
Science. 2020 Jul 3;369(6499):77-81
pubmed: 32376603
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Vaccine. 2022 Jan 3;40(1):52-58
pubmed: 34839992
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
J Med Virol. 2021 Sep;93(9):5560-5567
pubmed: 34019704
Asian Pac J Allergy Immunol. 2022 Sep;40(3):269-277
pubmed: 34717527
Lancet Microbe. 2020 Nov;1(7):e283-e289
pubmed: 33015652
Euro Surveill. 2022 Jan;27(2):
pubmed: 35027105
Ir J Med Sci. 2022 Mar 28;:
pubmed: 35344137
J Med Virol. 2022 Jan;94(1):35-38
pubmed: 34516026
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Science. 2021 Feb 5;371(6529):
pubmed: 33408181